Photo credit: finance.yahoo.com
Novo Nordisk’s GLP-1 medications, Ozempic and Wegovy, are set to be included in the forthcoming Medicare price negotiations scheduled for 2027, alongside 13 other pharmaceuticals.
In a recent discussion, Seana Smith and Brad Smith highlighted the key details surrounding this development on Morning Brief.
The previous round of negotiations conducted under the Inflation Reduction Act resulted in an average price decline of 22% for the selected medications. Given that Medicare currently spends approximately $41 billion annually on these drugs, the forthcoming negotiations could significantly impact healthcare expenses, particularly in the area of treatments for obesity. Nonetheless, uncertainties persist regarding how a potential return of a Trump administration might influence regulatory decisions, adding a layer of complexity to the anticipated outcomes.
For more expert analysis and insights regarding the latest trends in the market, you can explore additional episodes of Morning Brief here.
This post was contributed by Josh Lynch
Source
finance.yahoo.com